Delfi Diagnostics Inc.

DELFI Diagnostics is a pioneering biotechnology company specializing in non-invasive blood tests for early cancer detection using advanced machine learning and fragmentomics technology. Founded in 2018, DELFI's innovative approach aims to enhance lung cancer screening through the FirstLook Test, which analyzes fragments of cell-free DNA in blood samples. This next-generation liquid biopsy tool provides a powerful alternative to traditional screening methods that often rely heavily on finding known genetic mutations specific to cancer.

The core strategy underpinning DELFI’s technology is its ability to detect a wide array of previously unrecognized cancer-associated DNA fragments, thus improving the chances of early detection when cancer is most treatable. DELFI is backed by a team of leading experts in cancer biology, bioinformatics, and public health, ensuring a robust research and development foundation. The company actively collaborates with various health systems to facilitate the integration of its tests into routine healthcare practices, driving efforts to increase the accessibility and efficiency of cancer screening. With a strong emphasis on utilizing cutting-edge science and innovative solutions, DELFI Diagnostics strives to transform cancer care and ultimately save lives by making early detection of lung cancer more feasible and widespread.